Cleared Traditional

PHASE I CURETTE (K935822) - FDA 510(k) Clearance

Class I Obstetrics & Gynecology device.

K935822 · Phase I Corp. · Obstetrics & Gynecology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1994
Decision
146d
Days
Class 1
Risk

K935822 is an FDA 510(k) clearance for the PHASE I CURETTE. Classified as Curette, Uterine (product code HCY), Class I - General Controls.

Submitted by Phase I Corp. (Norwalk, US). The FDA issued a Cleared decision on April 28, 1994 after a review of 146 days - within the typical 510(k) review window.

This device falls under the Obstetrics & Gynecology FDA review panel, regulated under 21 CFR 884.4530 - the FDA obstetrics and gynecology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Obstetrics & Gynecology review framework, consistent with the majority of Class II 510(k) submissions.

View all Phase I Corp. devices

Submission Details

510(k) Number K935822 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 03, 1993
Decision Date April 28, 1994
Days to Decision 146 days
Submission Type Traditional
Review Panel Obstetrics & Gynecology (OB)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
14d faster than avg
Panel avg: 160d · This submission: 146d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HCY Curette, Uterine
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 884.4530
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.